Email this article Weekly topotecan regimen in the treatment of recurrent ovarian cancer: search for alternatives to upholding the quality of life
- Authors: Novikova E.G.1, Korneyeva I.A.1, Ronina E.A.1, Shcheltsyna S.A.1, Pashanov E.D.2
-
Affiliations:
- P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
- Medical Department, GlaxoSmithKline, Moscow
- Issue: No 2 (2010)
- Pages: 53-58
- Section: MAMMOLOGY. PHARMACOTHERAPY
- Published: 27.05.2010
- URL: https://ojrs.abvpress.ru/ojrs/article/view/231
- DOI: https://doi.org/10.17650/1994-4098-2010-0-2-53-58
- ID: 231
Cite item
Full Text
Abstract
The main goals of the study were to evaluate the efficacy and safety of intravenous topotecan (Hycamtin) used in a dose of 4 mg/m2 on days 1, 8, and 15 of a 28-day course of therapy in patients with recurrent ovarian cancer. The study revealed a number of benefits from use of topotecan in patients with this diagnosis.
Keywords
About the authors
E. G. Novikova
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical TechnologiesRussian Federation
I. A. Korneyeva
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical Technologies
Author for correspondence.
Email: andavakor@mail.ru
Russian Federation
E. A. Ronina
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical TechnologiesRussian Federation
S. A. Shcheltsyna
P.A. Herzen Moscow Research Institute of Oncological Studies, Russian Agency for Medical TechnologiesRussian Federation
E. D. Pashanov
Medical Department, GlaxoSmithKline, MoscowRussian Federation
References
Supplementary files
